{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mlecnik B"],"funding":["MEXT","The Society for Immunotherapy of Cancer (SITC)","La Ligue contre le Cancer","Japan-AMED","NIH/NCI","HalioDx","NCI NIH HHS"],"pagination":["418"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9856473"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(2)"],"pubmed_abstract":["<h4>Background</h4>The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear in Stage I/II, and in early-stage subgroups at risk. An international Society for Immunotherapy of Cancer (SITC) study evaluated the pre-defined consensus Immunoscore in tumors from 1885 AJCC/UICC-TNM Stage I/II CC patients from Canada/USA (Cohort 1) and Europe/Asia (Cohort 2).<h4>Methods</h4>Digital-pathology is used to quantify the densities of CD3+ and CD8+ T-lymphocyte in the center of tumor (CT) and the invasive margin (IM). The time to recurrence (TTR) was the primary endpoint. Secondary endpoints were disease-free survival (DFS), overall survival (OS), prognosis in Stage I, Stage II, Stage II-high-risk, and microsatellite-stable (MSS) patients.<h4>Results</h4>High-Immunoscore presented with the lowest risk of recurrence in both cohorts. In Stage I/II, recurrence-free rates at 5 years were 78.4% (95%-CI, 74.4-82.6), 88.1% (95%-CI, 85.7-90.4), 93.4% (95%-CI, 91.1-95.8) in low, intermediate and high Immunoscore, respectively (HR (Hi vs. Lo) = 0.27 (95%-CI, 0.18-0.41); <i>p</i> &lt; 0.0001). In Cox multivariable analysis, the association of Immunoscore to outcome was independent (TTR: HR (Hi vs. Lo) = 0.29, (95%-CI, 0.17-0.50); <i>p</i> &lt; 0.0001) of the patient's gender, T-stage, sidedness, and microsatellite instability-status (MSI). A significant association of Immunoscore with survival was found for Stage II, high-risk Stage II, T4N0 and MSS patients. The Immunoscore also showed significant association with TTR in Stage-I (HR (Hi vs. Lo) = 0.07 (95%-CI, 0.01-0.61); <i>P</i> = 0.016). The Immunoscore had the strongest (69.5%) contribution χ<sup>2</sup> for influencing survival. Patients with a high Immunoscore had prolonged TTR in T4N0 tumors even for patients not receiving chemotherapy, and the Immunoscore remained the only significant parameter in multivariable analysis.<h4>Conclusion</h4>In early CC, low Immunoscore reliably identifies patients at risk of relapse for whom a more intensive surveillance program or adjuvant treatment should be considered."],"journal":["Cancers"],"pubmed_title":["Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer."],"pmcid":["PMC9856473"],"funding_grant_id":["R21 CA251992 and R21 CA263262.","P30 CA008748","UMRS1138","Agreement number EL2019","Grants-in-aid for Scientific Research-S","P-DIRECT"],"pubmed_authors":["Zhang G","Masucci GV","Grizzi F","Musina AM","Jouret-Mourin A","Ohashi PS","Marincola FM","Wang J","Hazama S","Dundr P","Kirilovsky A","Patel P","Kawakami Y","Maby P","Furuhata T","Fox BA","Skalova H","Lee JJ","Knijn N","Pages F","Berger MD","Hafezi-Bakhtiari S","Hijazi A","Wang Y","Tatangelo F","Merkel S","Berger A","Rau TT","Konopasek B","Ciliberto G","Xu M","Wouters BG","Zlobec I","Ascierto PA","Nguyen LT","Paustian C","Mlecnik B","Bavi P","van de Water C","Marliot F","Nagano H","Torigoe T","Scripcariu DV","Van den Eynde M","Buttard B","Dijkstra J","Rajvik KN","Bindea G","El Sissy C","Ballesteros-Merino C","Kolwelter J","Leonard D","Kartheuser A","Suzuki N","Bifulco C","Lafontaine L","Vocka M","Spacek J","Han S","Geppert CI","Andersson EK","Nagtegaal ID","Pandya SJ","Delrio P","Majdi A","Botti G","Vliet SVL","Lugli A","Grutzmann R","Remue C","MacGregor HL","Okuno K","Patel JB","Shukla SN","Nemejcova K","Laghi L","Fujita T","Hartmann A","Fredriksen T","Maio M","Vora HH","Zavadova E","Vink-Borger E","Takemasa I","Shah B","Sato N","Lagorce C","Roehrl MHA","Galon J","Popivanova B","Petruzelka L"],"additional_accession":[]},"is_claimable":false,"name":"Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer.","description":"<h4>Background</h4>The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear in Stage I/II, and in early-stage subgroups at risk. An international Society for Immunotherapy of Cancer (SITC) study evaluated the pre-defined consensus Immunoscore in tumors from 1885 AJCC/UICC-TNM Stage I/II CC patients from Canada/USA (Cohort 1) and Europe/Asia (Cohort 2).<h4>Methods</h4>Digital-pathology is used to quantify the densities of CD3+ and CD8+ T-lymphocyte in the center of tumor (CT) and the invasive margin (IM). The time to recurrence (TTR) was the primary endpoint. Secondary endpoints were disease-free survival (DFS), overall survival (OS), prognosis in Stage I, Stage II, Stage II-high-risk, and microsatellite-stable (MSS) patients.<h4>Results</h4>High-Immunoscore presented with the lowest risk of recurrence in both cohorts. In Stage I/II, recurrence-free rates at 5 years were 78.4% (95%-CI, 74.4-82.6), 88.1% (95%-CI, 85.7-90.4), 93.4% (95%-CI, 91.1-95.8) in low, intermediate and high Immunoscore, respectively (HR (Hi vs. Lo) = 0.27 (95%-CI, 0.18-0.41); <i>p</i> &lt; 0.0001). In Cox multivariable analysis, the association of Immunoscore to outcome was independent (TTR: HR (Hi vs. Lo) = 0.29, (95%-CI, 0.17-0.50); <i>p</i> &lt; 0.0001) of the patient's gender, T-stage, sidedness, and microsatellite instability-status (MSI). A significant association of Immunoscore with survival was found for Stage II, high-risk Stage II, T4N0 and MSS patients. The Immunoscore also showed significant association with TTR in Stage-I (HR (Hi vs. Lo) = 0.07 (95%-CI, 0.01-0.61); <i>P</i> = 0.016). The Immunoscore had the strongest (69.5%) contribution χ<sup>2</sup> for influencing survival. Patients with a high Immunoscore had prolonged TTR in T4N0 tumors even for patients not receiving chemotherapy, and the Immunoscore remained the only significant parameter in multivariable analysis.<h4>Conclusion</h4>In early CC, low Immunoscore reliably identifies patients at risk of relapse for whom a more intensive surveillance program or adjuvant treatment should be considered.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T11:33:10.726Z","creation":"2025-04-04T11:33:10.726Z"},"accession":"S-EPMC9856473","cross_references":{"pubmed":["36672367"],"doi":["10.3390/cancers15020418"]}}